VivoSeq
Infectious Disease

RSV Infection

4

Pipeline Programs↗

5

Active Trials↗

6

Companies Involved↗

RSV Infection is an early-stage landscape with 4 programs across 6 companies. The most active players are Gilead, Enanta Pharmaceuticals, Inc, Pfizer. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

2 programs

Phase 2E

Enanta Pharmaceuticals, Inc

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3S

Shanghai Ark Biopharmaceutical Co., Ltd.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Obeldesivir

Gilead

Obeldesivir Placebo

Gilead

Zelicapavir

Enanta Pharmaceuticals, Inc

Phase 31

Rsvpref

Pfizer

Approved
No programs

Analysis

Trial Status

11

clinical trials

Recruiting4 · 36%
Completed4 · 36%
Terminated2 · 18%
Not yet recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.
Recruiting·MMeyer Children's Hospital IRCCS·N/A·NCT06856967·138 enrolled
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Recruiting·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 3·NCT06775405·180 enrolled
Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Recruiting·EEnanta Pharmaceuticals, Inc·Phase 2·NCT07482657·150 enrolled
A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.
Recruiting·Pfizer logoPfizer·Phase 3·NCT06866405·550 enrolled
Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination
Not yet recruiting·—·Phase 3·NCT07232706·1,000 enrolled
Safety Study of Oral BTA9881 to Treat RSV Infection
Completed·BBiota Scientific Management Pty Ltd·Phase 1·NCT00504907·63 enrolled
A Study of AK0529 in Adults Patients Hospitalized With RSV Infection
Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 2·NCT06942299·25 enrolled
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT05070546·1,124 enrolled
Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years
Completed·—·Phase 1·NCT05970744·60 enrolled
Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients
Terminated·PPulmocide Ltd·Phase 2·NCT03715023·5 enrolled
A Phase 2 Randomized, Placebo-controlled Study of the Safety and Efficacy of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Terminated·Gilead logoGilead·Phase 2·NCT06585150·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)